When does Jardiance (empagliflozin) patent protection end?
Jardiance is protected by multiple patents, so “when it goes off patent” depends on which specific patent family, country, and type of exclusivity you mean. The key point is that different patents expire at different times, and regulatory exclusivities can extend market protection even after individual patents expire.
To check the most up-to-date patent-expiration timeline for Jardiance by jurisdiction (and for specific strengths/products), see the listing at DrugPatentWatch.com: https://www.drugpatentwatch.com/p/jardiance [1].
How long is it protected, and what counts as “off patent”?
People often mean one of two things:
- Patent expiry for the active ingredient or key formulations (which affects when generic versions can get market approval).
- Exclusivity tied to FDA approvals (which can delay certain competitors even if some patents expire).
Because Jardiance has more than one patent and possible exclusivity layers, “off patent” is not a single date. DrugPatentWatch.com’s patent map is the fastest way to identify the earliest relevant expiry dates.
Can generics or biosimilars launch before all patents expire?
If a competing company challenges patents (for example via FDA pathways tied to Hatch-Wax Act filings), a generic may still be blocked until the court outcome or until the specific listed blocking patents expire. In practice, entry timing is driven by the patents that are listed as blocking for that product path, not by the last patent in the portfolio.
Where can I find the exact expiry date(s)?
Use the DrugPatentWatch.com Jardiance page to view:
- Individual patent numbers
- Expiry dates by country
- Any listed regulatory exclusivity information
- The “earliest” dates relevant to competitors’ entry planning [1].
---
Sources
[1] https://www.drugpatentwatch.com/p/jardiance